Last year, the Food and Drug Administration approved just 22 new therapeutic drugs, which is less than half the number approved in 2015. The cover story in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, explains why 2016 was such a lackluster year for new medicines, and whether it was an anomaly or the start of a longer term pharmaceutical slow-down.
Lisa M. Jarvis, a senior correspondent for C&EN, reports that the dip in approvals was partly due to delays. Some pharmaceutical manufacturing plants weren't in compliance with current standards and needed to be brought up to snuff. Also, the number of new cancer drugs, which often account for several drug approvals a year, suffered a cut. Only four drugs targeting cancer got the green light in 2016 whereas during the previous year, 14 did.
Ultimately, seven big pharma companies didn't get a single product to market in 2016. Forecasters expect numbers to turn around next year and return to the average of 30, including a boost in cancer drug approvals, but some industry watchers interpret last year's poor showing as a sign of uncertain times ahead.
###
The article, "The year in new drugs," is freely available here.
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With nearly 157,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact [email protected].
Follow us on Twitter | Facebook
Media Contact
Katie Cottingham
[email protected]
301-775-8455
@ACSpressroom
http://www.acs.org
############
Story Source: Materials provided by Scienmag
